ArticleJournal for immunotherapy of cancer2020

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.

Pei-Chang Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.